Compare GSK plc (GSK) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? GSK plc trades at $52.4 (market cap $101.34B), while YieldMax TSLA Option Income Strategy ETF trades at $26.52. The key difference: GSK plc pays a 3.49% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and GSK plc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GSK | TSLY | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $61.18 | $48.25 |
52-Week Low | $36.20 | $26.16 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
TSLY trades at $26.48, down 1.3% over the past day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a high distribution yield, with recent weekly dividends ranging from $0.26 to $0.52. Recent news highlights consistent distribution announcements from YieldMax, though coverage notes the fund's capped upside and volatility risks tied to its synthetic TSLA exposure.
The outlook for TSLY hinges on its ability to sustain high yields through option income strategies, but faces risks from Tesla's stock volatility and potential capital erosion. Investors should weigh the attractive income against significant downside exposure and limited growth potential in a bearish technical environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
